Ucb SA
OTC:UCBJF
Relative Value
The Relative Value of one UCBJF stock under the Base Case scenario is 127.33 USD. Compared to the current market price of 133.68 USD, Ucb SA is Overvalued by 5%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
UCBJF Competitors Multiples
Ucb SA Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
BE |
Ucb SA
OTC:UCBJF
|
23B USD | 4.4 | 67 | 20.7 | 48.4 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
728.1B USD | 21.3 | 138.7 | 62.7 | 72 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 16.9 | 46.8 | 34.2 | 37.3 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
JP |
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
704.3B JPY | 2.2 | 83.6 | 9.5 | 23.2 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
361.3B USD | 4.4 | 8.9 | 11.9 | 15.7 | ||
US |
Merck & Co Inc
NYSE:MRK
|
326.6B USD | 5.3 | 141.6 | 33.7 | 53.4 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
188.2B GBP | 5.1 | 39.5 | 140.7 | 225.7 | ||
CH |
Novartis AG
SIX:NOVN
|
181.4B CHF | 4.2 | 13.3 | 9.7 | 16.1 | ||
CH |
Roche Holding AG
SIX:ROG
|
171.2B CHF | 2.9 | 14.9 | 8.5 | 10.1 |